Marimed (MRMD) Long-Term Investments (2015 - 2024)

Marimed (MRMD) posted quarterly Long-Term Investments of $274000.0 for Q1 2024, up 23.98% quarter-over-quarter from $221000.0 in Q4 2023.

Marimed (MRMD) Long-Term Investments (2015 - 2024) Analysis & Trends

Marimed (MRMD) has reported Long-Term Investments for 10 consecutive years, with $274000.0 the latest figure, recorded in Q1 2024.

In Q1 2024, Long-Term Investments changed N/A year-over-year to $274000.0; the TTM figure through Mar 2024 stood at $274000.0 (changed N/A YoY), while the FY2023 annual figure was $221000.0, changed N/A from the prior year.
Long-Term Investments advanced to $274000.0 in Q1 2024 per MRMD's latest filing, from $221000.0 in the prior quarter.
Across five years, Long-Term Investments topped out at $2.1 million in Q3 2020 and bottomed at $89000.0 in Q2 2023.
Historically, Long-Term Investments has averaged $882936.5 across 5 years, with a median of $1.0 million in 2020.
Annual changes were most pronounced in 2020 — Long-Term Investments sank 97.1% — and 2022, when it climbed 16.06%.
Marimed's Long-Term Investments stood at $1.2 million in 2020, then sank by 78.47% to $251000.0 in 2021, then soared by 439.04% to $1.4 million in 2022, then tumbled by 83.67% to $221000.0 in 2023, then rose by 23.98% to $274000.0 in 2024.
Business Quant data shows MRMD's Long-Term Investments at $274000.0 in Q1 2024, $221000.0 in Q4 2023, and $164000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	92.58 Mn
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	-
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	63.23 Mn
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	1.14 Bn
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	149.10 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	60.00 Mn
10	Marimed	27.77 Mn	19.33 Mn	16.23 Mn	-

Download Data